DDrare: Database of Drug Development for Rare Diseases

41. 巨細胞性動脈炎
［臨床試験数：108，薬物数：111（DrugBank：32），標的遺伝子数：33，標的パスウェイ数：121］

Searched query = "Giant cell arteritis", "Temporal arteritis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 18F-FDG; ABT-494; AIN457; ANAKINRA; Abatacept; Adalimumab; Alendronate; Alendronate versus alfacalcidol (1-alpha OH vitamin D); Alfacalcidol; Anakinra; Anti-thymocyte globulin; BOSENTAN MYLAN; Baricitinib; Blood samples; Bosentan; CNTO 136; CORTANCYL; Combination Product: mavrilimumab; Cortancyl; Cortancyl ® 1 mg; Cortancyl ® 20 mg; Cortancyl ® 5 mg; Corticoids+ tocilizumab 8mg/Kg/4 weeks; Corticosteroid (CS); Corticosteroids; Corticosteroids for Systemic Use; Cosentyx; Cyclophosphamide; Cyclosporine; Diagnostic Test: 68-Ga HA-DOTATATE PET/CT; Dotatate; Encorton; Filgrastim; GSK2973327; Gevokizumab; Glucocorticoid Treatment; Glucocorticoids; Guselkumab; Hydroxychloroquine; Infliximab; KINERET; KPL-301; Kevzara; Kevzara ®; Kineret; Lodotra; Lodotra (delayed release prednisolone); MAVRILIMUMAB; METOJECT; Mavrilimumab; Methotrexate; Methotrexate treatment; Methylprednisolone; Naltrexone; Naltrexone Hydrochloride; Nivolumab; Other: 18F-FDG PET/CT; Other: IV steroids combination alone; Other: Questionnaires; Other: questionnaires; Over encapsulated prednisone; PET10; PET3; PREDNISOLONE; PREDNISONE; Pr; PredniSONE Tablets USP, 1 mg; PredniSONE Tablets USP, 2.5 mg; PredniSONE Tablets USP, 5 mg; PredniSONE Tablets, USP; Prednisolon 1 mg JENAPHARM; Prednisolon 5 mg JENAPHARM; Prednisolone; Prednisolone 5 mg JENAPHARM; Prednisone; Prednisone Capsules; Prednisone Tablets, USP; Prednisone and ustekinumab treatment; Prednisone therapy and pharmacokinetic; Prednisone treatment; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Rituximab; Ro 001-9265; Ro 001-9265/F02; Ro 001-9265/F03; Ro 001-9265/F04; Ro 487-7533/F10-04; RoActemra; RoActemra 162 mg solution for injection in pre-filled syringe; S78989; SAR153191; SARILUMAB; SECUKINUMAB; Sarilumab; Sarilumab SAR153191; Secukinumab; Secukinumab 300 mg, s.c.; Sirukumab; TOCILIZUMAB; TOCILIZUMAB SC; Tocilizumab; Tocilizumab + Glucocorticoids (GCs); Tocilizumab SC; Tocilizumab and IV steroids combination; Tocilizumab treatment; Treatment; Upadacitinib; Ustekinumab; Vitamin D; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03892785 (ClinicalTrials.gov)	January 27, 2020	26/3/2019	MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial	MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial	Giant Cell Arteritis	Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionnaires;Biological: Blood samples	Centre Hospitalier Universitaire Dijon	NULL	Recruiting	50 Years	N/A	All	200	Phase 3	France
2	EUCTR2018-002826-22-FR (EUCTR)	07/03/2019	21/11/2018	MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial - METOGIA	MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial - METOGIA	MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		CHU Dijon Bourgogne	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: no	200	Phase 3	France
3	NCT01791153 (ClinicalTrials.gov)	July 22, 2013	12/2/2013	An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)	A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis	Giant Cell Arteritis	Drug: Tocilizumab;Drug: Prednisone;Drug: Tocilizumab Placebo;Drug: Prednisone Placebo;Drug: Corticosteroids;Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	50 Years	N/A	All	251	Phase 3	United States;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;Austria
4	NCT00004686 (ClinicalTrials.gov)	February 1994	24/2/2000	Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis		Giant Cell Arteritis	Drug: methotrexate;Drug: prednisone	The Cleveland Clinic	NULL	Completed	50 Years	N/A	Both	300	Phase 2	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03892785
(ClinicalTrials.gov)

January 27, 2020

26/3/2019

MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial

Giant Cell Arteritis

Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionnaires;Biological: Blood samples

Centre Hospitalier Universitaire Dijon

NULL

Recruiting

50 Years

N/A

All

200

Phase 3

France

EUCTR2018-002826-22-FR
(EUCTR)

07/03/2019

21/11/2018

MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial - METOGIA

MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

CHU Dijon Bourgogne

NULL

Authorised-recruitment may be ongoing or finished

Female: no
Male: no

200

Phase 3

France

NCT01791153
(ClinicalTrials.gov)

July 22, 2013

12/2/2013

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Giant Cell Arteritis

Drug: Tocilizumab;Drug: Prednisone;Drug: Tocilizumab Placebo;Drug: Prednisone Placebo;Drug: Corticosteroids;Drug: Methotrexate

Hoffmann-La Roche

NULL

Completed

50 Years

N/A

All

251

Phase 3

United States;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;Austria

NCT00004686
(ClinicalTrials.gov)

February 1994

24/2/2000

Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis

Giant Cell Arteritis

Drug: methotrexate;Drug: prednisone

The Cleveland Clinic

NULL

Completed

50 Years

N/A

Both

300

Phase 2

NULL